Plymouth

The trials here

What the 19 trials at this site are about, from their registry records.

Conditions

• Prostate cancer6 trials
• Chronic lymphocytic leukaemia4 trials
• Follicular lymphoma2 trials
• Mantle cell lymphoma2 trials
• Asthma1 trial
• Diffuse large B-cell lymphoma1 trial
• Heart failure1 trial
• Hodgkin lymphoma1 trial
• Lung cancer1 trial
• Mesothelioma1 trial
• Metastatic breast cancer1 trial
• Multiple myeloma1 trial

Phase

• Phase 38 trials
• Phase 24 trials
• Phase 1/23 trials
• Phase 11 trial
• Phase 41 trial

Status

• Active, not recruiting8 trials
• Recruiting6 trials
• Completed3 trials
• Not yet recruiting2 trials

Lead sponsor

• AstraZeneca14 trials
• Acerta Pharma BV4 trials
• MedImmune LLC1 trial

Running trials

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· Phase 3· AstraZeneca· Source

• Recruiting

  Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

  NCT07181161· Phase 1/2· AstraZeneca· Source

• Recruiting

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· Phase 3· AstraZeneca· Source

• Recruiting

  Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

  NCT06651970· Phase 4· AstraZeneca· Source

• Recruiting

  Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  NCT06526793· Phase 2· AstraZeneca· Source

• Recruiting

  A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  NCT06549595· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

  NCT05951959· Phase 2· AstraZeneca· Source

• Recruiting

  AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

  NCT06106945· Phase 1/2· AstraZeneca· Source

• Active, not recruiting

  Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

  NCT06120491· Phase 3· AstraZeneca· Source

• Recruiting

  Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

  NCT05557695· AstraZeneca· Source

• Active, not recruiting

  Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

  NCT05367440· Phase 1/2· AstraZeneca· Source

• Active, not recruiting

  Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

  NCT04493853· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

  NCT02477696· Phase 3· Acerta Pharma BV· Source

• Active, not recruiting

  Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

  NCT02475681· Phase 3· Acerta Pharma BV· Source

• Active, not recruiting

  An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

  NCT02213926· Phase 2· Acerta Pharma BV· Source

• Active, not recruiting

  Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

  NCT01843374· Phase 2· MedImmune LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer3 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Follicular lymphoma2 recruiting
• Heart failure1 recruiting
• Hodgkin lymphoma1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Completed

  Patient Characteristics, Treatment Patterns and Outcomes of Patients With Severe Asthma Treated With Tezepelumab in the Real World; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres

  NCT06455462· AstraZeneca· Source

• Completed

  Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

  NCT02112526· Phase 1· Acerta Pharma BV· Source

• Completed

  Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· Phase 3· AstraZeneca· Source